A 6-month large-scale study into the safety of tamsulosin

British Journal of Clinical Pharmacology

Volumn 51, Issue 6, 2001, Pages 609-614

  Michel, M C ^a,c   Bressel, H U ^a   Goepel, M ^b   Rubben H ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Yamanouchi Pharma   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Benign prostatic hyperplasia; Drug interaction; Tamsulosin; Tolerability

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; PLACEBO; TAMSULOSIN; VERAPAMIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DESIGN; DRUG EXPOSURE; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REGRESSION ANALYSIS; SIDE EFFECT; SWEATING; TRAFFIC ACCIDENT; VERTIGO; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONAMIDES; TIME FACTORS; VERAPAMIL;

EID: 0034818252     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01388.x     Document Type: Article

References (28)

1. Endocrine and adrenergic pharmacological intervention in diseases of the prostate
2. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
3. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
4. Sustained-release alfuzosin, fanasteride and the combination of both in the treatment of benign prostatic hyperplasia
5. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: A combined analysis
6. Doxazosin in benign prostatic hyperplasia: Effects on blood pressure and urinary flow in normotensive and hypertensive men
7. Tamsulosin - A review of its pharmacological properties and therapeutic potential in the management of benign prostatic hyperplasia
8. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms sugestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)
9. 1-adrenoreceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses
10. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing
11. 1-adrenoceptor antagonism by tamsulosin and terazosin
12. 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled multicentre studies in patients with benign prostatic obstruction (symptomatic BPH)
13. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia
14. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia
15. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
16. 2-adrenergic receptors
17. Results of the PREDICT (Prospective European Doxazosin and Combination Therapy) trial
18. Alfuzosin for treatment of benign prostatic hypertrophy
19. Adverse effects of α1-adrenergic blocking drugs
20. Tamsulosin treatment of 19, 365 patients with lower urinary tract symptoms: Does comorbidity alter tolerability?
21. The pharmacovigilance of tamsulosin: Event data on 12484 patients
22. Combination antihypertensive therapy with terazosin and other antihypertensive agents: Results of clinical trials
23. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: Pharmacodynamic effect
24. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results
25. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine
26. A double-blind comparative study of doxazosin and prazosin when administered with β-blockers or diuretics
27. The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by β-blockers